Send this resource to your team or professional network.
GHK-Cu vs BPC-157 represent two distinct classes of research peptides: GHK-Cu is a copper-binding tripeptide studied for skin and tissue remodelling, while BPC-157 is a pentadecapeptide from gastric juice with gut and connective tissue associations. For primary sources, see Pickart et al. on GHK-Cu biology (PubMed) and Seiwerth et al. on BPC-157 research (PubMed).
GHK-Cu vs BPC-157: Key Research Differences
GHK-Cu and BPC-157 are different research materials. GHK-Cu combines the tripeptide Gly-His-Lys with copper(II). BPC-157 is the 15-residue peptide GEPPPGKPADDAGLV and has no specified metal cofactor. Their chemistry, analytical controls, and evidence do not support treating them as substitutes.
Evidence summary: GHK-Cu has a small human literature focused on topical formulations, including controlled studies with limited or neutral objective findings. BPC-157 relies on cell, animal, and small uncontrolled human reports. No published head-to-head study shows that either compound performs better.
Laboratory and educational context: This article covers structure, experimental models, analytical controls, and evidence limits. It provides no dosage, administration, cycle, stack, treatment, safety, or efficacy guidance.
GHK-Cu vs BPC-157 at a Glance
| Comparison point | GHK-Cu | BPC-157 |
|---|---|---|
| Identity | Gly-His-Lys complexed with copper(II) | Linear peptide, GEPPPGKPADDAGLV |
| Material category | Metal-peptide coordination complex | Synthetic pentadecapeptide |
| Approximate database mass | PubChem lists Cu-GHK at 403.92 g/mol; the declared coordination, protonation, salt, and hydration state can change the reported value | PubChem lists 1,419.5 g/mol |
| Common research context | Copper binding, fibroblast and keratinocyte response, collagen synthesis, matrix turnover | Endothelial migration, angiogenesis-related signalling, wound and musculoskeletal models |
| Evidence profile | Cell and animal studies; a few controlled human studies of topical formulations; a Phase 2 study is recruiting | Cell and animal studies; three small uncontrolled human reports; a Phase 2 study is recruiting |
| Main limitation | Results depend on copper state, formulation, and model; controlled human studies report limited or mixed findings | Human efficacy and safety evidence remains too small and uncontrolled for firm conclusions |
| Verified identity source | PubChem Cu-GHK record | PubChem BPC-157 record |
Conceptual scale comparison. The graphic distinguishes peptide length and copper coordination; it does not reproduce full chemical structures and is not to scale.
What Is GHK-Cu?
GHK names glycyl-L-histidyl-L-lysine. Pickart and Thaler first isolated this tripeptide from human serum in 1973.1 Researchers call its copper(II) complex GHK-Cu. PubChem treats Cu-GHK as a component compound of the peptide and copper, which gives laboratories a useful database identity rather than a complete lot specification.
Researchers should keep free GHK, free copper, and GHK-Cu separate in a protocol. Maquart and colleagues reported increased collagen synthesis in fibroblast culture after GHK-Cu exposure.2 Siméon and colleagues found changes in MMP-2 and TIMP-1/2 output; copper ions reproduced part of the response, while GHK alone did not reproduce that result.3 Those controls show why a label such as “copper peptide” cannot identify the active test condition.
Copper Coordination and the GHK Sequence
Spectroscopy gives GHK-Cu a defined chemical distinction. Freedman and colleagues found a mononuclear 1:1 complex at neutral pH and identified histidine imidazole nitrogen within the Cu(II) coordination environment.4 Laussac and colleagues reported three nitrogen ligands and one oxygen ligand in a square-planar arrangement across a mid-range pH interval.5
Buffer composition, pH, competing ligands, and free-copper content can alter speciation. A laboratory comparing lots should record those conditions and avoid treating the nominal peptide sequence as a full description of the test material.
What Is BPC-157?
BPC-157 is the 15-residue sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. PubChem records a molecular formula of C62H98N16O22 and a molecular weight of 1,419.5 g/mol.6 The research literature describes it as a synthetic fragment associated with a gastric “body protection compound.” Laboratories should classify the 15-mer as a defined synthetic test article.
Pentadecapeptide Structure and Research Origin
BPC-157 contains acidic and basic residues, lacks histidine, and carries no defined copper centre in its registered structure. Its net charge depends on pH and terminal or salt form. Laboratories should confirm the exact sequence, terminal state, counterion, and expected mass before choosing a reference standard.
Researchers have proposed several pathways from preclinical work. In endothelial-cell and rat hind-limb models, Hsieh and colleagues linked BPC-157 exposure with VEGFR2 internalization and Akt-eNOS signalling.7 Huang and colleagues reported endothelial migration and tube formation in culture alongside wound findings in a rat alkali-burn model.8 These studies support testable mechanisms. They do not establish a clinical outcome.
Sequence, Size, Charge, and Metal Binding
GHK-Cu contains three residues plus a coordinated Cu(II) ion. BPC-157 contains 15 residues and no specified metal cofactor. PubChem therefore lists BPC-157 at more than three times the mass of its Cu-GHK record. The larger sequence also supplies more peptide bonds and ionizable side chains.
A sound comparison uses pH-specific charge calculations and chemical forms confirmed in the laboratory. It does not assign each compound one permanent charge. For GHK-Cu, the protocol should account for copper occupancy and free copper. For BPC-157, the protocol should state the terminal form, salt or counterion, and sequence acceptance criteria. These variables affect chromatography, mass spectra, solubility, and assay behaviour.
Similarities Between GHK-Cu and BPC-157
Researchers place both compounds in repair-related experiments. Cell and animal studies examine wound closure, tissue remodelling, endothelial response, or inflammation-linked markers. Buyers compare them because those study areas overlap, although the molecules use different chemistry and proposed pathways.
Both fields face the same evidence problem. Formulation, species, cell type, exposure conditions, and endpoint can change the result. No published head-to-head study compares authenticated GHK-Cu and BPC-157 in one protocol. Researchers cannot use these published results to support broad human healing, recovery, or performance claims for either compound.
Laboratories need lot-specific identity, chromatographic purity, content, declared chemical form, vehicle controls, and predefined outcomes for both materials. GHK-Cu needs copper-speciation controls. BPC-157 needs sequence, terminal-form, and counterion checks.
Common Uses and Product Formats
Sellers and forum users discuss the compounds in different product categories. GHK-Cu appears in topical creams, gels, and serums marketed for skin appearance, collagen support, scalp or hair products, and wound-related care. The controlled human studies cited above tested topical tripeptide-copper formulations, including a cream for venous stasis ulcers and skin products after laser resurfacing.1516 Researchers should limit each conclusion to the finished formulation tested in that study. A research vial does not share the concentration, excipients, stability data, or manufacturing controls of a cosmetic cream.
BPC-157 appears in research-vial and injectable-use discussions tied to tendon, ligament, muscle, gastrointestinal, and general “recovery” claims. Researchers have focused on experimental cell and animal injury models, with a few small uncontrolled human reports.7811181920 Researchers have not established an authorized human indication, standard formulation, or dependable safety profile from that evidence.
Consumer products present GHK-Cu as a topical cosmetic ingredient. Online vendors present BPC-157 as an experimental vial. Researchers cannot treat marketing as evidence of efficacy or regulatory authorization. This article provides no preparation, injection, or dosing instructions.
In-Vitro Evidence
GHK-Cu has a long cell-culture record. Human fibroblast studies reported effects on collagen synthesis, MMP-2, TIMPs, growth, and growth-factor output.239 A skin-equivalent study also found changes in keratinocyte proliferation markers and integrin expression.10 Each experiment measured a narrow endpoint under a defined culture condition.
BPC-157 cell studies have focused on migration, proliferation, tube formation, and signalling. The endothelial studies cited above implicate ERK1/2 or VEGFR2-Akt-eNOS pathways.78 Researchers have also reported growth-hormone-receptor expression changes in rat tendon fibroblasts.11
No shared assay has compared authenticated GHK-Cu and BPC-157 lots under one protocol. Cross-paper comparisons mix cell types, formulations, concentrations, endpoints, and research teams. A new comparative study would need matched molar exposure ranges, vehicle controls, blinded analysis, and compound-specific controls.
Animal-Model Evidence
Maquart and colleagues used implanted wound chambers in rats and reported greater accumulation of collagen and other extracellular-matrix components after GHK-Cu exposure.12 A later irradiated rat-flap study found no significant improvement under its prespecified threshold, despite a different formulation and model.13 Researchers can get different results when they change the model.
BPC-157 studies have reported angiogenesis-related or repair endpoints in rat skin burns and hind-limb ischemia.78 A separate pharmacokinetic study in rats and dogs found rapid loss of parent peptide and species-dependent disposition.14 Animal pharmacokinetics cannot supply human exposure values or prove human benefit.
Human Evidence and Major Gaps
GHK-Cu has the stronger study designs in humans, though the results do not establish broad efficacy. In an evaluator-blinded randomized trial with 86 evaluable patients who had venous stasis ulcers, silver sulfadiazine reduced ulcer size more than a tripeptide-copper cream or placebo.15 A randomized study of 13 patients after carbon-dioxide laser resurfacing found no objective GHK-Cu advantage for erythema, wrinkles, or overall skin quality; participants reported higher satisfaction in the GHK-Cu group.16 ClinicalTrials.gov lists a recruiting Phase 2 topical GHK-Cu wound study with no posted results.17
BPC-157 human publications include a retrospective knee-pain report, a 12-person interstitial-cystitis pilot, and a two-person safety report.181920 None used a large randomized controlled design. An older Phase 1 registry record has unknown status and no posted results.21 A recruiting Phase 2 hamstring-strain trial targets 120 participants, with primary completion estimated for 2027; registration describes a plan, not a result.22
Neither evidence base supports a head-to-head clinical ranking. Findings from a finished topical formulation cannot transfer to an unrelated research vial, route, salt form, or model.
Match the Compound to the Research Question
Researchers should define the assay objective before selecting a compound. A copper-coordination study needs GHK, copper, GHK-Cu, vehicle, and speciation controls. A BPC-157 endothelial or tendon model needs an authenticated 15-mer, vehicle, a suitable sequence control, and endpoints chosen before data collection.
A direct comparison would require one shared biological model and an endpoint that both compounds could affect. Researchers would need to match molar exposure, characterize each preparation, randomize samples, blind outcome scoring, and report negative results. Without that design, a “better” claim ranks unlike experiments.
Anglo Peptides provides separate product and lot-document pages for GHK-Cu research material and BPC-157 research material. Researchers can also consult the Peptide Research Centre for background articles and the research peptide catalogue for available materials. The peptide calculator supports laboratory calculations. Product pages and tools do not replace primary literature or a laboratory protocol.
Identity, Purity, and COA Interpretation
A certificate of analysis should match the compound name, lot number, sample identifier, test date, and vial label. Laboratories should then separate five questions:
- Identity: Does mass spectrometry support the expected molecular species and relevant adduct pattern?
- Purity: Does a qualified chromatographic method resolve the main peak from related impurities?
- Content: Does a quantitative assay support the stated amount of peptide or complex in the vial?
- Chemical form: Does the report state the salt, counterion, hydration state, terminal form, and copper status where relevant?
- Method scope: Do the method, reference standard, acceptance criteria, and raw chromatogram support the reported result?
HPLC area percentage does not prove identity or net content. A dominant chromatographic peak can coexist with an incorrect sequence, water, counterions, residual solvent, or an inaccurate fill amount. Mass spectrometry supports identity but does not give a complete impurity or content assessment by itself. ICH Q2(R2) calls for specificity and suitable orthogonal procedures when one method cannot discriminate the analyte from impurities.23 FDA peptide-quality research has used HPLC-MS/MS to find and characterize peptide-related impurities.24
Laboratories use a COA to document the tested sample, method, and date. The document cannot prove therapeutic suitability, sterility, endotoxin control, efficacy, or stability beyond tested conditions.
FAQ
What is the main difference between GHK-Cu and BPC-157?
GHK-Cu is a copper(II) complex of the three-residue GHK peptide. BPC-157 is a synthetic 15-residue peptide with no specified metal cofactor. Their sequences, masses, chemical controls, and common experimental models differ.
Are GHK-Cu and BPC-157 interchangeable?
No. Substitution would change the test article, controls, analytical method, and mechanistic question. A protocol should name one authenticated compound and its exact chemical form.
Has GHK-Cu been compared directly with BPC-157?
A PubMed and ClinicalTrials.gov search found no head-to-head primary study as of August 19, 2026. Existing claims rely on indirect comparisons across different models.
Which has stronger human evidence?
GHK-Cu has controlled human studies in topical formulations, but those studies reported limited or neutral objective findings. BPC-157 has small uncontrolled reports and a recruiting Phase 2 trial without results. Neither supports broad clinical claims.
How should a laboratory verify either material?
Match the vial to a lot-specific COA, confirm sequence or complex identity by mass spectrometry, review chromatographic purity and raw data, verify net content with a quantitative method, and record the declared salt, terminal, hydration, or copper state.
Are these products approved for human use in Canada?
Anglo offers the catalogue items discussed here for laboratory research. Health Canada assigns an eight-digit DIN to each drug it authorizes for sale and lists authorized drugs in the Drug Product Database.2526 A research listing or COA does not create product authorization.
References
1. Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nature New Biology. 1973.
2. Maquart FX, et al. Stimulation of collagen synthesis in fibroblast cultures by GHK-Cu. FEBS Letters. 1988.
3. Siméon A, et al. GHK-Cu stimulates MMP-2 expression by fibroblast cultures. Life Sciences. 2000.
4. Freedman JH, et al. Structure of the GHK-Cu(II) complex in solution. Biochemistry. 1982.
5. Laussac JP, et al. NMR and EPR investigation of copper(II) and GHK. Biochemical Journal. 1983.
6. PubChem. BPC-157, CID 9941957.
7. Hsieh MJ, et al. BPC-157, VEGFR2 activation, and angiogenesis models. Journal of Molecular Medicine. 2017.
8. Huang T, et al. BPC-157 in a rat alkali-burn wound model and endothelial assays. Drug Design, Development and Therapy. 2015.
9. Pollard JD, et al. Copper tripeptide effects in normal and irradiated fibroblasts. Archives of Facial Plastic Surgery. 2005.
10. Kang YA, et al. Copper-GHK, integrin expression, and p63 in keratinocytes. Archives of Dermatological Research. 2009.
11. Chang CH, et al. BPC-157 and growth-hormone-receptor expression in tendon fibroblasts. Molecular Medicine Reports. 2014.
12. Maquart FX, et al. GHK-Cu and connective-tissue accumulation in rat wounds. Journal of Clinical Investigation. 1993.
13. Parker NP, et al. Topical GHK-Cu in an irradiated rat wound model. Otolaryngology–Head and Neck Surgery. 2013.
14. He L, et al. BPC-157 pharmacokinetics, distribution, metabolism, and excretion in rats and dogs. Frontiers in Pharmacology. 2022.
15. Bishop JB, et al. Randomized trial of wound-healing agents for venous stasis ulcers. Journal of Vascular Surgery. 1992.
16. Miller TR, et al. GHK-Cu skin products after carbon-dioxide laser resurfacing. Archives of Facial Plastic Surgery. 2006.
17. ClinicalTrials.gov. NCT07437586: Topical GHK-Cu gel for acute skin wound healing.
18. Lee E, Padgett B. BPC-157 and knee pain: retrospective report. Alternative Therapies in Health and Medicine. 2021.
19. Lee E, et al. BPC-157 in interstitial cystitis: pilot study. Alternative Therapies in Health and Medicine. 2024.
20. Lee E, Burgess K. BPC-157 in two adults: pilot safety report. Alternative Therapies in Health and Medicine. 2025.
21. ClinicalTrials.gov. NCT02637284: PCO-02 safety and pharmacokinetics trial, no posted results.
22. ClinicalTrials.gov. NCT07437547: BPC-157 for acute hamstring muscle strain repair.
23. International Council for Harmonisation. ICH Q2(R2): Validation of Analytical Procedures. 2023.
24. U.S. Food and Drug Administration. Regulatory science report: complex mixtures and peptides.
25. Health Canada. Drug Product Database: access the database.
26. Health Canada. Regulating health products.
Related Peptide Research Articles
Explore more: BPC-157 Arginate vs Acetate, Why GHK-Cu Stings, BPC-157 vs TB-500 Canada.
